A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study.
about
Plasmacytoid dendritic cells in allogeneic hematopoietic cell transplantation: benefit or burden?Concise review: Sowing the seeds of a fruitful harvest: hematopoietic stem cell mobilizationThe CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.Targeting stem cell niches and trafficking for cardiovascular therapyMobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.Mobilization of hematopoietic stem/progenitor cells: general principles and molecular mechanisms.Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with β-thalassemia majorIn vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectorsPlerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs.Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens.Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.Novel agents and approaches for stem cell mobilization in normal donors and patients.Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept.Progenitor cell mobilization and recruitment: SDF-1, CXCR4, α4-integrin, and c-kit.Physiology and pharmacology of plerixafor.Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.Current clinical indications for plerixaforPlerixafor for mobilization of blood stem cells in autologous transplantation: an update.Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective.Optimizing autologous cell grafts to improve stem cell gene therapy.Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.A Lentiviral CXCR4 overexpression and knockdown model in colorectal cancer cell lines reveals plerixafor-dependent suppression of SDF-1α-induced migration and invasion.Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients.Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor.Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison.New strategies for stem cell mobilization.Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients.Blood graft composition after plerixafor injection in patients with NHL.Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients.A new source of mesenchymal stem cells for articular cartilage repair: MSCs derived from mobilized peripheral blood share similar biological characteristics in vitro and chondrogenesis in vivo as MSCs from bone marrow in a rabbit model.CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients.Dynamic cellular phynotyping defines specific mobilization mechanisms of human hematopoietic stem and progenitor cells induced by SDF1α versus synthetic agents.Plerixafor: what we still have to learn.Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin's Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.Stem cell homing using local delivery of plerixafor and stromal derived growth factor-1alpha for improved bone regeneration around Ti-implants.Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes.Aerobic exercise in humans mobilizes HSCs in an intensity-dependent manner.Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma.
P2860
Q26773952-41DC4BE8-086E-478F-A912-B782F0C3640AQ26825518-FCD2029C-46A7-46A3-AC63-0CC883B48018Q34432943-36D309C1-D0FD-457E-885C-999594305071Q34475689-019A106D-3888-431C-938C-DA2C281CD973Q36445393-BD184597-54F0-4D51-B7D8-095E4576EE05Q36912497-83432796-333E-4B44-90F0-A538191828CEQ37208384-C9239BA7-C78C-446F-A2D2-6E6094A450BAQ37394036-F06F2175-BFC4-4A44-9434-8EDF0006E03BQ37785509-9B624BEB-4864-440C-BB06-ED45A3193528Q37827058-54865AE4-CFE6-43C1-8E73-CC78FEB6922EQ37921284-1AB90BD3-A1C6-4609-8EA5-983885D8D635Q37923309-7252A912-7052-4B44-BBFE-E077C92BCF19Q37943423-FEFF2764-E8DF-46B8-AA28-0270CD6BF7AFQ38037185-DCF0B290-8578-421B-B7ED-DC78B7FD9D49Q38157897-02E173D4-4313-4C8A-815B-4C292D8409CCQ38160461-E7BD160B-C255-4B89-92B7-15BD44F12262Q38177784-FF7B2D24-B584-47EA-87A3-D92BFDA99DE4Q38199707-7E1F5346-A356-40D1-9322-1F0981630599Q38200909-C3680CD9-E372-4DB6-ADEE-64F609E3871FQ38349208-BF47CAFF-171C-4BC6-9267-C1F0CA48AA95Q38815488-24E7F888-66B9-4C67-BC16-93D4B454856DQ38880504-6E5CAC64-D3E6-41C3-B50C-090C18F6E4C4Q39460665-318C3173-45C4-476A-860A-4D7F1877E75DQ39724267-9E6841B1-60B6-496B-A1F2-7A4E43335978Q39958361-84586B08-ED7B-422F-A901-03BFE96904E6Q40896003-45281C2F-B530-4E39-AADB-94AA11494903Q41104670-7A16722B-CD09-40ED-B432-BE0BD92C5ACFQ43524297-02B69ABF-A9A8-45F0-8B7C-2EF7D9045073Q44353274-E2E49B7F-E5FC-4562-97C1-FD6EB113AE93Q45513822-08335D62-EE01-45DD-96F9-925D018938D6Q45752095-D547AD1D-14C9-4535-B4A0-33479CE0B405Q46767119-4BB4CD5B-C6A9-4444-8834-A90000A02C63Q47256928-A1864C17-73C8-4E93-B8DE-7E261C4EFB31Q48138880-8F904248-6949-415F-A25C-148C30939836Q48747463-060D59C5-DD17-432A-8D67-ECB42520FCB2Q50150301-2B173B23-A129-41AD-9B21-A0B6D776E019Q50850464-C8077F9D-3B1F-4397-AF7E-CC89140B96C7Q50959656-8213F3E5-7D80-464D-872B-06859FD91B12Q51048096-D699E272-9709-4F0A-AA8B-E93DC108A1E2Q51057684-410616FF-42B2-40DA-A8CF-E2C59941E5BB
P2860
A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
A combination of granulocyte-c ...... of a European phase II study.
@en
A combination of granulocyte-colony-stimulating factor
@nl
type
label
A combination of granulocyte-c ...... of a European phase II study.
@en
A combination of granulocyte-colony-stimulating factor
@nl
prefLabel
A combination of granulocyte-c ...... of a European phase II study.
@en
A combination of granulocyte-colony-stimulating factor
@nl
P2093
P1433
P1476
A combination of granulocyte-c ...... of a European phase II study.
@en
P2093
Anthony Dick Ho
Falk Dillmann
Frederik Wenz
Gary Calandra
Julian Topaly
Mario Schubert
Marlon Romano Veldwijk
Patrick Wuchter
Stefan Fruehauf
Stephanie Laufs
P304
P356
10.3109/14653240903121245
P577
2009-01-01T00:00:00Z